Insmed Incorporated (0JAV.L)
USD 66.21
(-7.07%)
USD 66.21
(-7.07%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.32 Billion USD | -19.72% |
| 2022 | 1.65 Billion USD | 33.21% |
| 2021 | 1.24 Billion USD | 56.19% |
| 2020 | 796.15 Million USD | 7.26% |
| 2019 | 742.29 Million USD | 22.78% |
| 2018 | 604.55 Million USD | 30.84% |
| 2017 | 462.04 Million USD | 94.17% |
| 2016 | 237.95 Million USD | -33.26% |
| 2015 | 356.55 Million USD | 54.44% |
| 2014 | 230.86 Million USD | 30.8% |
| 2013 | 176.49 Million USD | 14.94% |
| 2012 | 153.56 Million USD | 9.82% |
| 2011 | 139.83 Million USD | -28.75% |
| 2010 | 196.26 Million USD | 54.91% |
| 2009 | 126.69 Million USD | 2562.78% |
| 2008 | 4.75 Million USD | -75.6% |
| 2007 | 19.5 Million USD | -31.21% |
| 2006 | 28.34 Million USD | 23.95% |
| 2005 | 22.87 Million USD | 75.77% |
| 2004 | 13.01 Million USD | -56.36% |
| 2003 | 29.81 Million USD | 5.31% |
| 2002 | 28.3 Million USD | -60.47% |
| 2001 | 71.6 Million USD | -30.29% |
| 2000 | 102.71 Million USD | 1839.71% |
| 1999 | 5.29 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.81 Billion USD | 56.17% |
| 2024 Q1 | 1.15 Billion USD | -12.84% |
| 2024 Q3 | 2.05 Billion USD | 13.42% |
| 2023 FY | 1.32 Billion USD | -19.72% |
| 2023 Q3 | 1.32 Billion USD | -7.94% |
| 2023 Q2 | 1.43 Billion USD | -5.18% |
| 2023 Q1 | 1.51 Billion USD | -8.37% |
| 2023 Q4 | 1.32 Billion USD | 0.37% |
| 2022 Q2 | 1.05 Billion USD | -8.67% |
| 2022 Q4 | 1.65 Billion USD | 66.51% |
| 2022 Q1 | 1.15 Billion USD | -7.25% |
| 2022 FY | 1.65 Billion USD | 33.21% |
| 2022 Q3 | 994.81 Million USD | -5.56% |
| 2021 Q1 | 692.39 Million USD | -13.03% |
| 2021 Q3 | 1.31 Billion USD | 6.67% |
| 2021 Q4 | 1.24 Billion USD | -5.2% |
| 2021 Q2 | 1.22 Billion USD | 77.61% |
| 2021 FY | 1.24 Billion USD | 56.19% |
| 2020 Q4 | 796.15 Million USD | -5.3% |
| 2020 FY | 796.15 Million USD | 7.26% |
| 2020 Q1 | 676.52 Million USD | -8.86% |
| 2020 Q2 | 885.36 Million USD | 30.87% |
| 2020 Q3 | 840.71 Million USD | -5.04% |
| 2019 FY | 742.29 Million USD | 22.78% |
| 2019 Q1 | 595.91 Million USD | -1.43% |
| 2019 Q2 | 802.78 Million USD | 34.71% |
| 2019 Q4 | 742.29 Million USD | -2.73% |
| 2019 Q3 | 763.11 Million USD | -4.94% |
| 2018 Q2 | 724.24 Million USD | -6.33% |
| 2018 FY | 604.55 Million USD | 30.84% |
| 2018 Q4 | 604.55 Million USD | -8.61% |
| 2018 Q1 | 773.15 Million USD | 67.33% |
| 2018 Q3 | 661.51 Million USD | -8.66% |
| 2017 Q4 | 462.04 Million USD | -8.72% |
| 2017 Q3 | 506.2 Million USD | 205.61% |
| 2017 Q2 | 165.64 Million USD | -17.45% |
| 2017 FY | 462.04 Million USD | 94.17% |
| 2017 Q1 | 200.65 Million USD | -15.67% |
| 2016 Q4 | 237.95 Million USD | -13.98% |
| 2016 FY | 237.95 Million USD | -33.26% |
| 2016 Q1 | 327.7 Million USD | -8.09% |
| 2016 Q2 | 299.67 Million USD | -8.55% |
| 2016 Q3 | 276.64 Million USD | -7.69% |
| 2015 Q4 | 356.55 Million USD | -7.57% |
| 2015 Q1 | 206.15 Million USD | -10.7% |
| 2015 FY | 356.55 Million USD | 54.44% |
| 2015 Q2 | 408.5 Million USD | 98.16% |
| 2015 Q3 | 385.74 Million USD | -5.57% |
| 2014 Q4 | 230.86 Million USD | -1.94% |
| 2014 Q3 | 235.44 Million USD | 56.85% |
| 2014 Q1 | 166.62 Million USD | -5.6% |
| 2014 FY | 230.86 Million USD | 30.8% |
| 2014 Q2 | 150.11 Million USD | -9.91% |
| 2013 FY | 176.49 Million USD | 14.94% |
| 2013 Q1 | 143.01 Million USD | -6.87% |
| 2013 Q2 | 138.72 Million USD | -3.0% |
| 2013 Q4 | 176.49 Million USD | -7.08% |
| 2013 Q3 | 189.95 Million USD | 36.93% |
| 2012 Q3 | 152.45 Million USD | 12.06% |
| 2012 Q2 | 136.05 Million USD | 2.1% |
| 2012 FY | 153.56 Million USD | 9.82% |
| 2012 Q1 | 133.25 Million USD | -4.71% |
| 2012 Q4 | 153.56 Million USD | 0.72% |
| 2011 Q4 | 139.83 Million USD | -4.27% |
| 2011 Q3 | 146.06 Million USD | -18.98% |
| 2011 Q2 | 180.28 Million USD | -5.35% |
| 2011 FY | 139.83 Million USD | -28.75% |
| 2011 Q1 | 190.47 Million USD | -2.95% |
| 2010 Q1 | 126.89 Million USD | 0.15% |
| 2010 FY | 196.26 Million USD | 54.91% |
| 2010 Q4 | 196.26 Million USD | 54.54% |
| 2010 Q3 | 127 Million USD | -0.32% |
| 2010 Q2 | 127.4 Million USD | 0.41% |
| 2009 Q3 | 124.62 Million USD | -0.54% |
| 2009 Q2 | 125.3 Million USD | -3.48% |
| 2009 Q1 | 129.82 Million USD | 2628.46% |
| 2009 FY | 126.69 Million USD | 2562.78% |
| 2009 Q4 | 126.69 Million USD | 1.66% |
| 2008 FY | 4.75 Million USD | -75.6% |
| 2008 Q1 | 14.81 Million USD | -24.04% |
| 2008 Q4 | 4.75 Million USD | -41.61% |
| 2008 Q3 | 8.14 Million USD | -31.85% |
| 2008 Q2 | 11.95 Million USD | -19.28% |
| 2007 Q4 | 19.5 Million USD | -13.65% |
| 2007 FY | 19.5 Million USD | -31.21% |
| 2007 Q1 | 15.7 Million USD | -44.59% |
| 2007 Q2 | 25.92 Million USD | 65.03% |
| 2007 Q3 | 22.58 Million USD | -12.89% |
| 2006 Q3 | 45.08 Million USD | -20.71% |
| 2006 Q4 | 28.34 Million USD | -37.12% |
| 2006 Q2 | 56.85 Million USD | -9.24% |
| 2006 Q1 | 62.64 Million USD | 173.9% |
| 2006 FY | 28.34 Million USD | 23.95% |
| 2005 Q2 | 33.73 Million USD | -17.97% |
| 2005 Q3 | 25.74 Million USD | -23.7% |
| 2005 FY | 22.87 Million USD | 75.77% |
| 2005 Q4 | 22.87 Million USD | -11.15% |
| 2005 Q1 | 41.12 Million USD | 216.08% |
| 2004 Q3 | 11.6 Million USD | -38.46% |
| 2004 Q1 | 25.33 Million USD | -15.01% |
| 2004 FY | 13.01 Million USD | -56.36% |
| 2004 Q4 | 13.01 Million USD | 12.1% |
| 2004 Q2 | 18.86 Million USD | -25.57% |
| 2003 Q2 | 22.57 Million USD | -11.02% |
| 2003 Q4 | 29.81 Million USD | -8.58% |
| 2003 Q3 | 32.61 Million USD | 44.46% |
| 2003 Q1 | 25.37 Million USD | -10.38% |
| 2003 FY | 29.81 Million USD | 5.31% |
| 2002 Q1 | 62.63 Million USD | -12.52% |
| 2002 Q2 | 55.3 Million USD | -11.71% |
| 2002 Q3 | 49.34 Million USD | -10.78% |
| 2002 FY | 28.3 Million USD | -60.47% |
| 2002 Q4 | 28.3 Million USD | -42.63% |
| 2001 Q4 | 71.6 Million USD | -7.97% |
| 2001 FY | 71.6 Million USD | -30.29% |
| 2001 Q1 | 93.23 Million USD | -9.23% |
| 2001 Q3 | 77.81 Million USD | -9.91% |
| 2001 Q2 | 86.36 Million USD | -7.37% |
| 2000 Q4 | 102.71 Million USD | 104.82% |
| 2000 Q3 | 50.15 Million USD | -2.63% |
| 2000 Q2 | 51.5 Million USD | 675.36% |
| 2000 FY | 102.71 Million USD | 1839.71% |
| 2000 Q1 | 6.64 Million USD | 0.0% |
| 1999 FY | 5.29 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -59.896% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -41.907% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -70.957% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -703.507% |
| bluebird bio, Inc. | 619.16 Million USD | -114.78% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -956.735% |
| Imunon, Inc. | 21.91 Million USD | -5967.309% |
| Editas Medicine, Inc. | 499.15 Million USD | -166.419% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 95.016% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 60.369% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -10.94% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 59.1% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 5.617% |
| Verastem, Inc. | 149.71 Million USD | -788.228% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.359% |
| Waters Corporation | 4.62 Billion USD | 71.258% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.653% |
| Biogen Inc. | 26.84 Billion USD | 95.046% |
| Nektar Therapeutics | 398.03 Million USD | -234.102% |
| Perrigo Company plc | 10.8 Billion USD | 87.697% |
| Dynavax Technologies Corporation | 997.09 Million USD | -33.371% |
| Illumina, Inc. | 10.11 Billion USD | 86.848% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -4603.659% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -70.415% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -497.663% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1924.413% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 80.562% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -704.402% |
| Evolus, Inc. | 188.99 Million USD | -603.625% |
| Adicet Bio, Inc. | 207.29 Million USD | -541.519% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -573.659% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 95.98% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -546.192% |
| FibroGen, Inc. | 423.52 Million USD | -213.99% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 87.644% |
| OPKO Health, Inc. | 2.01 Billion USD | 33.895% |
| Homology Medicines, Inc. | 47.05 Million USD | -2726.013% |
| Geron Corporation | 394.07 Million USD | -237.457% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 65.277% |
| Exelixis, Inc. | 2.94 Billion USD | 54.804% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -260.888% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -761.371% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -2.218% |
| Zoetis Inc. | 14.28 Billion USD | 90.691% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -126.072% |
| Abeona Therapeutics Inc. | 64 Million USD | -1977.805% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 94.149% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2276.874% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 55.525% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 59.265% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -113.966% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 23.276% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -26.742% |
| TG Therapeutics, Inc. | 329.58 Million USD | -303.486% |
| Incyte Corporation | 6.78 Billion USD | 80.392% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 27.525% |